¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Receptor, Nerve Growth Factor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
  • safety factor
    ¾ÈÀü°è¼ö
  • skin vascular permeability factor
    ÇǺÎÇ÷°üÅõ°úÀÎÀÚ
  • vascular permeability factor
    Ç÷°üÅõ°úÀÎÀÚ
  • virulence factor
    µ¶¼ºÀÎÀÚ, ¹ßº´ÀÎÀÚ
  • virus inhibitory factor
    ¹ÙÀÌ·¯½º¾ïÁ¦ÀÎÀÚ
  • accelerator nerve
    ÃËÁø½Å°æ
  • anococcygeal nerve
    Ç×¹®²¿¸®½Å°æ, Ç×¹®¹Ì°ñ½Å°æ
  • anterior interosseous nerve syndrome
    ¾Õ»À»çÀ̽ŰæÁõÈıº, Àü¹æ°ñ°£½Å°æÁõÈıº
  • accessory nerve
    ´õºÎ½Å°æ, ºÎ½Å°æ
  • antidromic nerve impulse
    ¿ªÀüµµ½Å°æÀÚ±Ø
  • articular nerve
    °üÀý½Å°æ
  • auditory nerve
    ¼Ó±Í½Å°æ, û(°¢)½Å°æ
  • auriculotemporal nerve
    ±Ó¹ÙÄû°üÀڽŰæ, À̰³ÃøµÎ½Å°æ
  • autonomic nerve
    ÀÚÀ²½Å°æ
  • autonomic nerve fiber
    ÀÚÀ²½Å°æ¼¶À¯
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
  • afferent nerve
    µé½Å°æ
  • afferent nerve fiber
    µé½Å°æ¼¶À¯
  • alveolar nerve
    ÀÌÆ²½Å°æ
  • alveolar nerve block
    ÀÌÆ²½Å°æ¸¶Ãë, Ä¡Á¶½Å°æ±¹¼Ò¸¶Ãë
  • ampullar nerve
    ÆØ´ë½Å°æ
  • anococcygeal nerve
    Ç×¹®²¿¸®½Å°æ
  • anterior interosseous nerve syndrome
    ¾Õ»À»çÀ̽ŰæÁõÈıº
  • antidromic nerve impulse
    ¿ªÀüµµ½Å°æÈïºÐ
  • articular nerve
    °üÀý½Å°æ
  • auditory nerve
    (¢¡vestibulocochlear nerve) ¼Ó±Í½Å°æ
  • auriculotemporal nerve
    ±Ó¹ÙÄû°üÀڽŰæ
  • autonomic nerve
    ÀÚÀ²½Å°æ
  • autonomic nerve fiber
    ÀÚÀ²½Å°æ¼¶À¯
  • autonomic nerve plexus
    ÀÚÀ²½Å°æ¾ó±â
  • axillary nerve
    °Üµå¶û½Å°æ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
  • radiation weighting factor
    ¹æ»ç¼±°¡Áß°è¼ö
  • realization factor
    ½ÇÇöÀÎÀÚ(ãùúÞì×í­).
  • recruitment factor
    ´©°¡¿äÀÎ(׫ʥé©ì×).
  • reducing factor
    ȯ¿øÀÎÀÚ.
  • relaxing factor
    ÀÌ¿ÏÀÎÀÚ(ì¬èÐì×í­).
  • Arnolds nerve
    ¹ÌÁֽŰæÀ̰³Áö
  • Cranial nerve
    ³ú½Å°æ(ÒàãêÌè)
  • Glossopharyngeal nerve
    ¼³ÀνŰæ(àßìÖãêÌè)
  • Hypogastric nerve
    ÇϺ¹ºÎ½Å°æ(ù»ÜÙÝ»ãêÌè)
  • Internal carotid nerve
    ¼Ó¸ñµ¿¸Æ
  • Jacobsons nerve
    ¾ßÄß½¼½Å°æ
  • NANC nerve fiber
    ºñÀÚÀ²½Å°æ¼º ½Å°æ¼¶À¯(¾Æµå·¹³¯¸°,Äݸ°
  • abducent nerve (vi)
    °«µ¹¸²½Å°æ
  • accelerans nerve =acceleratory n.
    ÃËÁø½Å°æ(õµòäãêÌè).
  • accelerator nerve
    ÃËÁø½Å°æ(õµòäãêÌè).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
  • population growth
    Àα¸¼ºÀå(ËöË´ËÛËö).
  • relative growth
    »ó´ëÀû »ýÀå(ßÓÓßîÜßæíþ)
  • somatotropic hormone =growth h.
    ¼ºÀå(à÷íþ)È£¸£¸ó.
  • specific growth rate
    ƯÁ¤Áõ½ÄÀ²
  • subperichondrial growth
    ¿¬°ñ¸·ÇϼºÀå
  • swarming growth
    À¯ÁÖ¼ºÀå
  • synchronous growth
    µ¿Á¶Áõ½Ä(¡­ñòãÖ), µ¿ Á¶¹ßÀ°(¡­Û¡ëÀ).
  • tissue growth factors
  • total growth
    ÃÑÁõ½Ä·®(õÅñòãÖåÖ).
  • tumor growth
    Á¾¾ç¼ºÀå
  • tumor growth,cell aggreagation in
    ¡­¿¡¼­ ¼¼Æ÷ÀÀÁý(¼¼Æ÷ÀÀ±«)
  • tumor growth,cell cycle and
    ¼¼Æ÷ÁÖ±â¿Í ¡­
  • tumor growth,kinetics of
    ¡­ÀÇ ¼Óµµ·Ð(¿ªµ¿, µ¿ÅÂ)
  • tumor growth,latent period in
    ¡­Àẹ±â
  • absorbed dose conversion factor
    Èí¼ö¼±·®º¯È¯°è¼ö
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 18
FGF father's grandfather; fibroblast growth factor; fresh gas flow
FGFA fibroblast growth factor, acidic
FGFB fibroblast growth factor, basic
GCF growth-rate-controlling factor
GFRP growth factor response protein
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 18
IGF GH)-insulin-like growth factor
GGF Glial Growth Factor
GGF2 Glial growth factor 2
GRF Growth Hormone Releasing Factor
GDF Growth differentiation factor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • electrochemical nerve impulse
    Àü±â È­ÇÐ ½Å°æ ÀÓÆÞ½º
  • epressor nerve
    °¨¾Ð ½Å°æ
    ½ÉÀå¿¡ ÀÖ´Â ±¸½É¼º ½Å°æ. ´ëµ¿¸Æ °³±¸ºÎ¿Í ´ëµ¿¸Æ±Ã¿¡ ºÐÆ÷µÇ¾î ÀÖÀ¸¸ç, Ç÷¾ÐÀÌ ºñÁ¤»óÀ¸·Î »ó½ÂÇßÀ» ¶§ À̸¦ °¨¼Ò½ÃŰ´Â Á¶Àý ÀÛ¿ëÀ» ÇÑ´Ù. ÀÌ ½Å°æÀº µ¿¹°ÀÇ ¹ÌÁֽŰæ Áٱ⠼ӿ¡ ´Ù¹ß·Î ÀÖÀ¸³ª, ÁýÅä³¢³ª °í¾çÀÌ µî¿¡¼­´Â ÀÏÁ¤ÇÑ °æ°ú Áß¿¡ ¹ÌÁֽŰ濡¼­ ºÐ¸®µÇ¾î °æºÎ¿¡¼­ ¹ÌÁֽŰæ°ú ³ª¶õÈ÷ Á¸ÀçÇÑ´Ù. »ç¶÷ÀÇ °¨¾Ð ½Å°æ ¼¶À¯´Â ¹ÌÁÖ½Å°æ ¼Ó¿¡ Æ÷ÇÔµÇ¾î ½ÉÀåÀÇ °¡Áö¶ó ºÎ¸£°í ÀÖ´Ù. ½Å°æ ¼¼Æ÷ÀÇ ¼¼Æ÷ü´Â ¹ÌÁֽŰæÀÇ Àý»ó ½Å°æÀý ¼Ó¿¡ ÀÖ°í, ½Å°æ ¼¶À¯´Â ¿¬¼öÀÇ °í¸³ ½Å°æ ÇÙ¿¡ À̸¥´Ù. °¨¾Ð ½Å°æÀº Ç÷¾ÐÀ» ³»¸®´Â ÀÛ¿ë»Ó ¾Æ´Ï¶ó, Ç÷¾ÐÀÌ Áö³ªÄ¡°Ô ³·À» ¶§¿¡´Â ¹Ý´ë·Î Ç÷¾ÐÀ» ¿Ã¸®´Â ¹Ý»çÀÛ¿ë¿¡µµ °ü°èÇÑ´Ù´Â ¼³µµ ÀÖ´Ù.
  • excavation of optic nerve head
    ½Ã½Å°æ À¯µÎ ÇÔ¸ô
  • facial cranial nerve
    ¾È¸é µÎ°³ ½Å°æ, ¾È¸é ½Å°æ
  • facial nerve block
    ¾È¸é ½Å°æ Â÷´Ü
  • facial nerve palsy
    ¾È¸é ½Å°æ ¸¶ºñ
  • femoral nerve
    ´ëÅð ½Å°æ
  • femoral nerve stretch test
    ´ëÅð ½Å°æ ½ÅÀü ½ÃÇè
  • free nerve ending
    ÀÚÀ¯ ½Å°æ Á¾¸», À¯¸® ½Å°æ Á¾¸»
  • frontal nerve
    ÀüµÎ ½Å°æ
  • fusimotor nerve fiber
    ¹æÃß ¿îµ¿ ½Å°æ ¼¶À¯
  • iliohypogastric nerve
    Àå°ñ ÇϺ¹ ½Å°æ
    ¿ä ½Å°æÃÑ
  • incisive nerve block anesthesia
    ÀýÄ¡ ½Å°æ Àü´Þ ¸¶Ãë
  • inferior alveolar nerve block
    ÇϾǰø Àü´Þ ¸¶Ãë, ÇÏÄ¡Á¶½Å°æ Àü´Þ ¸¶Ãë
  • inferior alveolar nerve branch
    ÇÏÄ¡Á¶ ½Å°æÁö
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 18
galactopoietic factor <protein> Pituitary lactogenic hormone (23 kD) Synthesised on endoplasmic reticulum bound ribosomes as preprolactin that has an N terminal signal peptide that is cleaved from the mature form. The conversion of preprolactin to prolactin has been much used as an assay for membrane insertion.
(18 Nov 1997)
macrophage-activating factor An agent that stimulates macrophages to attack and ingest cancer cells. They are secreted by stimulated lymphocytes that prime macrophages to become non-specifically cytotoxic to tumours.
They also modulate the expression of macrophage cell surface ia antigens. One maf is interferon-gamma (interferon type II). Other factors antigenically distinct from ifn-gamma have also been identified.
(12 Dec 1998)
macrophage colony-stimulating factor <growth factor> A glycoprotein growth factor that causes the committed cell line to proliferate and mature into macrophages.
A cytokine synthesised by mesenchymal cells that stimulates pluripotent stem cells of bone marrow into differentiating towards the production of monocytes (mononuclear phagocytes).
The compound stimulates the survival, proliferation, and differentiation of haematopoietic cells of the monocyte-macrophage series. It is a disulfide-bonded glycoprotein dimer with a mw of 70 kD and binds to a single class of high affinity receptor which is identical to the product of the c-fms proto-oncogene.
See: colony-stimulating factors.
Chemical name: Colony-stimulating factor 1
Acronym: M-CSF
(12 Dec 1998)
macrophage inhibition factor <cytokine> A group of lymphokines (including a 14 kD glycoprotein) produced by activated T lymphocytes that reduces macrophage mobility and probably increases macrophage macrophage adhesion.
(18 Nov 1997)
radiation weighting factor In radiation protection, a factor weighting the absorbed dose of radiation of a specific type and energy for its effect on tissue.
See: equivalent dose.
(05 Mar 2000)
maise factor <molecular biology, plant biology> A naturally occurring cytokinin, originally isolated from maize seeds. Its riboside is also a cytokinin.
(18 Nov 1997)
mammotropic factor <protein> Pituitary lactogenic hormone (23 kD) Synthesised on endoplasmic reticulum bound ribosomes as preprolactin that has an N terminal signal peptide that is cleaved from the mature form. The conversion of preprolactin to prolactin has been much used as an assay for membrane insertion.
(18 Nov 1997)
receptors, atrial natriuretic factor Cell surface proteins that bind atrial natriuretic factor with high affinity and trigger intracellular changes influencing the behaviour of cells.
(12 Dec 1998)
receptors, colony-stimulating factor Cell surface receptors for colony-stimulating factors, local mediators, and hormones that regulate the survival, proliferation, and differentiation of haemopoietic cells.
(12 Dec 1998)
receptors, granulocyte-colony-stimulating factor Receptors that bind and internalise granulocyte-colony-stimulating factor. Their mw is believed to be 150 kD. These receptors are found mainly on a subset of myelomonocytic cells.
(12 Dec 1998)
receptors, granulocyte-macrophage colony-stimulating factor Receptors that bind and internalise the granulocyte-macrophage stimulating factor. Their mw is believed to be 84 kD. The most mature myelomonocytic cells, specifically human neutrophils, macrophages, and eosinophils, express the highest number of affinity receptors for this growth factor.
(12 Dec 1998)
receptors, macrophage colony-stimulating factor Glycoproteins of mw 165 kD which are encoded by the c-fms proto-oncogene. The binding of csf-1 to its receptors activates an intrinsic tyrosine kinase activity resulting in autophosphorylation of the receptors on tyrosine, rapid receptor down-regulation, and phosphorylation of as yet unidentified physiologic substrates that initiate a mitogenic response.
(12 Dec 1998)
receptors, tumour necrosis factor Cell surface receptors that bind tumour necrosis factor and trigger changes which influence the behaviour of cells. The two recognised tumour necrosis factor receptors are designated alpha and beta receptors. Both receptors bind both alpha and beta tumour necrosis factors with high affinity, and both are members of the nerve growth factor receptor family.
(12 Dec 1998)
G factor The single common variance or factor that is common to (i.e., empirically intercorrelates with) different intelligence tests (general).
A substance required for the growth of a specific organism.
(05 Mar 2000)
Castle's intrinsic factor A mucoprotein normally secreted by the epithelium of the stomach and that binds vitamin B12, the intrinsic factor/B12 complex is selectively absorbed by the distal ileum, though only the vitamin is taken into the cell.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 18
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 18
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 18
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 18
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 18
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 18
ÅëÇÕ°Ë»ö ¿Ï·á